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Introduction 
Chronic obstructive pulmonary disease (COPD) is 
characterized by airflow limitation that is not fully 
reversible, with progressive lung function deterioration. 
The single most important cause of COPD is cigarette 
smoking.The symptoms of COPD, including progressive 
dyspnoea, chronic cough and sputum production, are 
disabling and have a substantial impact on quality of life. 
The disease is associated with substantial morbidity and 
mortality worldwide, and is expected to become the 
third leading cause of death and the fifth leading cause of 
disability by the year 2020 (I). 
Although the burden of COPD is considerable, the 
disease remains poorly understood and an inadequately 
managed health problem.There is a lack of recognition of 
COPD among patients and healthcare professionals, 
which contributes to the underdiagnosis and under- 
treatment of the disease (2). COPD has also tended to 
receive only limited attention from healthcare decision 
makers, particularly in comparison with other, high 
profile chronic diseases such as heart disease or cancer. 
As a result, COPD has received healthcare funding at a 
level far below what would be expected given the 
mortality and morbidity impact of the disease (2), 
contributing further to the sub-optimal management of 
the condition in hospitals and primary care practices. 
Improving the diagnosis and treatment of patients with 
COPD will necessitate raising awareness of the burden 
of the disease among patients, physicians and healthcare 
decision makers. A key step towards this aim is obtaining 
comprehensive information about the impact of the 
disease on patients, the healthcare system and society. 
Yet few studies have attempted to quantify the impact of 
this disease.This provided the rationale for Confronting 
COPD in North America and Europe, the first large-scale 
international survey to assess the burden of COPD.The 
survey interviewed 3265 patients and 905 physicians in 
eight countries, to collect information on clinical 
outcomes, management practices, healthcare resource 
use and lost workplace productivity. It included patients 
who reported a physician diagnosis of COPD, and 
patients who reported symptoms consistent with a 
diagnosis of chronic bronchitis for at least two years 
prior to the survey.The clinical results of the survey (3) 
showed that many patients with COPD were suffering 
frequent, debilitating symptoms that were poorly 
managed with available treatments, with both patients 
and physicians reporting a need for further education on 
the nature of the disease and effective management 
strategies. 
This supplement reports the results of economic 
analyses of the Confronting COPD survey, which used 
quantified measures of healthcare resource use and 
workplace absence to estimate the per patient cost of 
COPD to the healthcare system and society. Results are 
reported for Canada, France, Italy, the Netherlands, 
Spain, the United Kingdom and the United States of 
America. The economic analyses clearly highlight the 
considerable impact of COPD in individual countries, 
with direct and indirect costs totalling up to US$4l I9 
per patient per year. In almost every country, the 
majority of COPD-related healthcare costs were 
accounted for by inpatient hospitalizations, suggesting 
that a shift away from unscheduled emergency 
treatment, towards improved management of the disease 
in primary care, could substantially reduce the economic 
impact of COPD. It could, however, be argued that even 
this survey underestimates the societal cost of COPD. 
The disease in this survey is characterized by the self- 
reported knowledge of a physician’s diagnosis or 
symptoms justifying a diagnosis of chronic bronchitis, and 
there might still be patients not included in this analysis 
such as undiagnosed patients who underestimate 
symptoms and have not received diagnosis yet. 
Furthermore, indirect costs for the disease might be 
underestimated, as cost for permanent disability is not 
well covered, and the cost for early mortality is 
impossible to evaluate with the current methodology. It 
was recently shown that in Sweden 58% of the total 
societal cost, including permanent disability, was 
attributable to indirect costs (4) and in an earlier study, 
the indirect costs were 61% of total cost when both 
permanent disability and the cost for early deaths were 
included (5). 
Ways in which the management of COPD could be 
improved were suggested by the survey: up to 30% of 
patients reporting symptoms of the disease had not 
received a diagnosis, and up to 75% of patients reported 
that they were not receiving any regular medication for 
treatment of their respiratory condition.The survey also 
revealed that the economic impact of COPD in each 
country was particularly marked in patients with severe 
disease.These results suggest that, to alleviate the burden 
of COPD in North America and Europe, a high priority 
should be given to interventions aimed at delaying the 
progression of disease, such as smoking cessation. As a 
minimum, health care education should include 
knowledge about the impact of smoking on health and 
basic skills in smoking cessation strategies. Early diagnosis, 
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together with efforts against the smoking habit, is 
extremely important, and all involved in early handling of 
COPD patients such as GP surgeries and hospital clinics 
must have easy access to spirometry and know how to 
perform and evaluate screening spirometries. 
The pharmacological and non-pharmacological 
treatment modalities should be evaluated and used after 
individual assessment. Rehabilitation programmes should 
be available on a much larger scale than today (6) and 
there is a great need to transfer the knowledge of COPD 
as a systemic disease with multiple manifestations into 
daily clinical behaviour and practice. 
There is also an increasing body of evidence from 
large-scale database studies, showing reduced mortality 
and morbidity in patients with moderate and severe 
COPD treated with inhaled corticosteroids (7-l 0). 
Combining an inhaled corticosteroid with a long-acting 
bronchodilator may further reduce the burden of 
morbidity, as indicated in a recent clinical trial (I I). 
It is anticipated that the results of the economic 
analysis of the Confronting COPD survey will be useful 
in informing patients, physicians and healthcare decision 
makers of the societal impact of COPD. Raising 
awareness of the burden of COPD in individual 
countries is an important step towards highlighting the 
need for improved diagnosis and treatment, which will be 
necessary to reduce the impact of this disease on the 
patient, healthcare system and society as a whole.That is 
an effort of such dimensions that it needs a clear official 
strategy and resource allocation from governments and 
all involved in health care. 
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